Abvc biopharma announces letter to shareholders

Fremont, ca, sept. 13, 2022 (globe newswire) -- via newmediawire -- abvc biopharma, inc. (nasdaq: abvc), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, cns, and ophthalmology, today announced a letter to shareholders.

ABVC Ratings Summary

ABVC Quant Ranking